The history of haploidentical stem cell transplantation: a trip from the bench to the bedside

References

• Robinson TM, O’Donnell PV, Fuchs EJ, et al. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol. 2016;53(2):90–97.
   PubMed Web of Science ®Google Scholar
• Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med. 1978 Dec 1;148(6):1687–1698.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994 Dec 1;84(11):3948–3955.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New Engl J Med. 1998 Oct 22;339(17):1186–1193.
   PubMed Web of Science ®Google Scholar
• Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005 May 20;23(15):3447–3454.
   PubMed Web of Science ®Google Scholar
• Luznik L, Engstrom LW, Iannone R, et al. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002;8(3):131–138.
   PubMed Web of Science ®Google Scholar
• O’Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377–386.
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-Haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282–288.
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, O’Donnell PV, Eapen M, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021;137(3):420–428.
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285–4291.
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Cooke KR, Gamper CJ, et al. Increasing the dose of total body irradiation to decrease graft failure associated with HLA-haploidentical transplantation for patients with severe hemoglobinopathies. A single institution prospective clinical trial. Lancet Haematol. 2019;6(4):e183–e193. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506220/.
   PubMed Web of Science ®Google Scholar
• DeZern AE, Zahurak ML, Symons HJ, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4(8):1770–1779.
   PubMed Web of Science ®Google Scholar
• DeZern AE, Zahurak M, Symons HJ, et al. Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood. 2023 Jun 22;141(25):3031–3038.
   PubMed Web of Science ®Google Scholar
• DeZern AE, Eapen M, Wu J, et al. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022 Sep 1;9(9):e660–e669.
   PubMed Web of Science ®Google Scholar
• Ghosh N, Karmali R, Rocha V, et al. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016;34(26):3141–3149.
   PubMed Web of Science ®Google Scholar
• Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938–947.
   PubMed Web of Science ®Google Scholar
• McCurdy SR, Kasamon YL, Kanakry CG, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017;102(2):391–400.
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Bolaños-Meade J, Prince GT, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33(28):3152–3161.
   PubMed Web of Science ®Google Scholar
• Imus PH, Tsai H-L, Luznik L, et al. Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv. 2019;3(17):2608–2616.
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Fuchs EJ, Zahurak M, et al. Shortened-duration tacrolimus after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2018;24(5):1022–1028.
   PubMed Web of Science ®Google Scholar
• DeZern AE, Elmariah H, Zahurak M, et al. Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2020;26(11):2075–2081.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Forde PM, Symons H, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2014;20(3):314–318.
   PubMed Web of Science ®Google Scholar
• Imus PH, Blackford AL, Bettinotti M, et al. Major histocompatibility mismatch and donor choice for second allogeneic bone marrow transplant. Biol Blood Marrow Transplant. 2017;23(11):1887–1894.
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Hamadani M, Wu J, et al. Post-Transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023 Jun 22;388(25):2338–2348.
   PubMed Web of Science ®Google Scholar
• Duléry R, Malard F, Brissot E, et al. Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation. Bone Marrow Transplant. 2023;58(11):1215–1222.
   PubMed Web of Science ®Google Scholar
• Gallardo-Pérez MM, Gutiérrez-Aguirre CH, Olivares-Gazca JC, et al. More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses? Hematology. 2024;29(1):2313357.
   PubMed Web of Science ®Google Scholar